Institute for Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn, Bonn, Germany.
German Center for Infection Research (DZIF), partner site Bonn-Cologne, Bonn, Germany.
Parasitol Res. 2021 Dec;120(12):4125-4143. doi: 10.1007/s00436-020-07026-2. Epub 2021 Feb 6.
Filariae are vector-borne parasitic nematodes that are endemic worldwide, in tropical and subtropical regions. Important human filariae spp. include Onchocerca volvulus, Wuchereria bancrofti and Brugia spp., and Loa loa and Mansonella spp. causing onchocerciasis (river blindness), lymphatic filariasis (lymphedema and hydrocele), loiasis (eye worm), and mansonelliasis, respectively. It is estimated that over 1 billion individuals live in endemic regions where filarial diseases are a public health concern contributing to significant disability adjusted life years (DALYs). Thus, efforts to control and eliminate filarial diseases were already launched by the WHO in the 1970s, especially against lymphatic filariasis and onchocerciasis, and are mainly based on mass drug administration (MDA) of microfilaricidal drugs (ivermectin, diethylcarbamazine, albendazole) to filarial endemic areas accompanied with vector control strategies with the goal to reduce the transmission. With the United Nations Sustainable Development Goals (SDGs), it was decided to eliminate transmission of onchocerciasis and stop lymphatic filariasis as a public health problem by 2030. It was also requested that novel drugs and treatment strategies be developed. Mouse models provide an important platform for anti-filarial drug research in a preclinical setting. This review presents an overview about the Litomosoides sigmodontis and Acanthocheilonema viteae filarial mouse models and their role in immunological research as well as preclinical studies about novel anti-filarial drugs and treatment strategies.
丝虫是一种经媒介传播的寄生线虫,在全球的热带和亚热带地区流行。重要的人类丝虫种包括盘尾丝虫、班氏吴策线虫和布鲁线虫,以及罗阿丝虫和曼森线虫,分别引起盘尾丝虫病(河盲症)、淋巴丝虫病(淋巴水肿和鞘膜积液)、罗阿丝虫病(眼丝虫病)和曼森线虫病。据估计,有超过 10 亿人生活在流行地区,这些地区的丝虫病是公共卫生关注的问题,导致大量残疾调整生命年(DALYs)的损失。因此,世界卫生组织(WHO)在 20 世纪 70 年代就已经发起了控制和消除丝虫病的努力,特别是针对淋巴丝虫病和盘尾丝虫病,主要基于在丝虫病流行地区大规模使用杀微丝蚴药物(伊维菌素、乙胺嗪、阿苯达唑)进行药物治疗,并辅以媒介控制策略,以减少传播。随着联合国可持续发展目标(SDGs)的提出,决定到 2030 年消除盘尾丝虫病的传播,并停止淋巴丝虫病作为公共卫生问题。此外,还要求开发新的药物和治疗策略。小鼠模型为临床前环境中的抗丝虫药物研究提供了一个重要平台。本文综述了利什曼原虫和旋尾丝虫的丝虫小鼠模型及其在免疫研究以及新型抗丝虫药物和治疗策略的临床前研究中的作用。